New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the...

Related Keywords

Rick Baehner ,Precision Oncology At Exact Sciences ,Gleason Grade ,Precision Oncology ,Exact Sciences ,Exact Science Oncotype ,Prostate Score ,Exact Sciences Corp ,